What Acenac N Treats: Main Uses and Benefits

The combination is generally applied to address chronic pain that presents with mixed pain signals, which include inflammatory and nerve-related discomfort.

---

Quick Fact: Relief for Mixed Pain and Discomfort

Primary Symptom Areas	Key Benefits
Neuropathic sensations, Joint stiffness, Chronic aching	Assists with functional stability, Contributes to improved comfort

---

This medication is applied in clinical settings marked by symptoms related to increased neurological or muscular activity, such as neuropathic pain, a therapeutic domain associated with conditions presenting with systemic or localized discomfort. It helps address distressing sensations like burning, tingling, and shooting discomfort. Acenac N is also commonly used for symptomatic management of chronic musculoskeletal disorders including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, and is relevant in situations like complex chronic low back pain with sciatic involvement. This supportive relief contributes to easing the overall symptom load and assists with maintaining functional stability.

“The medication is applied in scenarios where additional management of discomfort is required when symptoms cluster into patterns.”

Acenac N is a combination drug containing Aceclofenac (a non-steroidal anti-inflammatory drug or NSAID) and Pregabalin (an anticonvulsant), used primarily to manage neuropathic pain and related inflammatory conditions like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

---

Who Can Use Acenac N?

It is generally prescribed for adults with pain due to nerve damage (neuropathic pain) or for musculoskeletal pain associated with inflammation. Use is determined by a healthcare provider after a complete assessment of the patient’s condition and medical history.

---

Who Should Not Use Acenac N? (Contraindications)

Use of Acenac N is generally contraindicated in individuals with certain pre-existing conditions. Consult your doctor immediately if you have any of the following:

• Allergy or hypersensitivity to Aceclofenac, Pregabalin, or other NSAIDs (such as aspirin or ibuprofen).
• Active or recurrent gastrointestinal (GI) ulcers or bleeding.
• Severe heart failure or other severe heart problems.
• Severe kidney or liver impairment.
• A history of asthma, bronchospasm, or allergic reactions (like angioedema or rhinitis) after taking NSAIDs.
• Pregnancy, especially in the third trimester, and breastfeeding women.
• Children and adolescents under 18 years of age (safety and efficacy are not established).

---

Interactions with other medicines and products

The regulatory documentation for Acenac N, which combines Aceclofenac and Pregabalin, establishes an interaction profile defined by two main domains: additive pharmacodynamic effects and the risk of altered drug exposure for co-administered medicines. This profile restricts combinations that augment adverse effects.

Co-administration with other NSAIDs, including aspirin or COX-2 inhibitors, is explicitly advised against due to the heightened risk of serious gastrointestinal adverse events and bleeding. Pharmacodynamic interactions also involve substances that affect the central nervous system (CNS). Combining Acenac N with CNS depressants (such as opioids or benzodiazepines) is documented to carry a risk of additive effects, including increased respiratory depression and somnolence.

The NSAID component increases the risk of hemorrhage when used with anticoagulants (e.g., Warfarin), corticosteroids, or SSRIs. Regarding drug exposure, the Aceclofenac component is documented to cause decreased elimination of certain medicines, leading to increased plasma concentrations. This applies to agents such as Lithium and Digoxin. Furthermore, a timing-based constraint exists for the use of the NSAID component after Mifepristone administration; a separation period of 8 to 12 days is specified to maintain Mifepristone's therapeutic effect. Specific caution is noted for elderly or dehydrated patients taking ACE-inhibitors or ARBs due to a documented increase in the risk of acute renal insufficiency.

Complementary Mechanisms: Peripheral vs. Central Modulation

This combination product exerts its effect by simultaneously targeting the peripheral chemical cascade and the central electrical transmission pathway. The two active ingredients operate independently—one acting at the site of tissue involvement to limit signal generation, and the other acting within the spinal cord to dampen signal amplification—resulting in a dual physiological modulation of nociception.

---

️ Blocking Inflammatory Mediator Synthesis (Aceclofenac)

The Aceclofenac component works primarily by acting as an inhibitor of Cyclo-oxygenase (COX) enzymes, predominantly the COX-2 isoform. This inhibition blocks the synthesis of prostaglandins (PGE2), which are key chemical messengers that sensitize peripheral nerve endings. The resulting physiological effect is a reduction in the chemical messengers that drive local tissue response and peripheral nociceptor sensitization.

---

Modulating Central Nerve Hyperexcitability (Pregabalin)

The Pregabalin component acts centrally by binding with high affinity to the alpha2-delta subunit of Voltage-Gated Calcium Channels (VGCCs) in the presynaptic terminal. This functional modulation reduces the calcium-dependent release of excitatory neurotransmitters, such as Glutamate, in pathways responsible for transmission. The key physiological consequence is the functional modulation of overactive neuronal firing, influencing the transmission rate of excessive nerve signaling within the central pathways.

How to Use Acenac N: Official Administration Guidelines

Acenac N, a fixed-dose combination, must be administered according to specific guidelines. The proper use of the medication focuses on a fixed schedule and requires adherence to special instructions for ingestion and discontinuation.

---

Official Route, Form, and Frequency

Feature	Official Labeled Instruction
Route of Administration	For oral administration only.
Approved Form	The medication is supplied as an oral tablet.
Dosing Schedule	Typically prescribed to be taken twice daily, which aligns with the recommended Aceclofenac daily dose in divided amounts.

---

Key Administration Conditions and Use Patterns

Tablets should be taken preferably with or after food to help minimize potential gastrointestinal discomfort, and the tablet must be swallowed whole with liquid; it should not be crushed, chewed, or divided.

Acenac N should be used for the shortest duration necessary to achieve symptomatic control. Discontinuation of treatment, particularly related to the Pregabalin component, must involve a gradual reduction of the dose over a minimum of one week to prevent potential withdrawal symptoms.

---

Population-Specific Dosing Rules

• Patients with Impaired Function: The dose of the Pregabalin component must be adjusted for individuals with reduced renal function. For patients with mild hepatic impairment, the daily dose of the Aceclofenac component is typically halved to 100 mg.
• Older Adults: The lowest effective dose should be used for the shortest duration possible.
• Pediatric Use: The medication is not recommended for use in children due to a lack of sufficient clinical data.

Research evidence / Overview of studies for Acenac N

Evidence for Use in Chronic Low Back Pain with Sciatic Involvement

Research has explored the use of the fixed-dose combination (FDC) of Aceclofenac and Pregabalin in adult patients whose chronic low back pain includes a nerve-related component, often referred to as sciatica. Studies conducted during periods of increased symptom activity examined how symptoms evolved in the observed populations, typically over short-to-intermediate time intervals. This research included randomized controlled trials (RCTs) and observational studies. These studies monitored outcomes related to physical discomfort and daily functioning. Findings describe patterns observed in the studies related to changes in scores for neuropathic symptoms, such as burning or tingling discomfort.

However, the evidence is limited regarding the long-term effects of the specific combination. Follow-up durations were often limited in FDC trials, meaning data on the durability or sustainability of these observed outcomes beyond a few months are not fully established. Research so far indicates that while the components have established roles, the FDC-specific evidence often comes from modest sample sizes and may vary across studies.

---

Evidence for Use in Musculoskeletal Disorders

This part will describe the research base relevant to chronic joint conditions, detailing the systematic reviews and trials that examined the NSAID component's influence on measures of stiffness and joint pain. The research explored outcomes related to inflammatory states, such as joint stiffness and tenderness. What remains uncertain is the need for the second component, Pregabalin, in cases of pure musculoskeletal pain that do not present with a noticeable neuropathic component. Comparative evidence is lacking for the FDC against standard dual-therapy approaches in strictly inflammatory populations.

---

Evidence for Use in Neuropathic Pain

The Pregabalin component was evaluated in numerous voluminous and high-quality RCTs for its role in neuropathic pain conditions. These studies explored short-term symptom changes, tracking outcomes such as the intensity of nerve-related pain and associated issues like sleep interference. Despite the extensive research available for Pregabalin, limited information is available for the fixed combination specifically in the context of pure, non-mixed neuropathic pain.

---

What Remains Uncertain About Acenac N

One key limitation is that comparative evidence is lacking in trials directly assessing the FDC against common standard-of-care combination regimens. The evidence quality varies across studies, and some older trials for the individual components have methodological issues. Furthermore, research does not determine whether an individual will respond similarly to the group patterns described in the studies. The findings describe group patterns, not personal outcomes, and evidence highlights what is known—and what is still uncertain—about this dual-action treatment.

How to Store and Dispose of Acenac N

Acenac N Tablet must be stored according to regulatory requirements to preserve the stability of its components. The medication must be kept in a cool and dry place with the temperature maintained below 30 C.

---

Mandatory Storage Conditions

Storage Factor	Requirement
Temperature	Store below 30 C
Protection	Protect from light and moisture
Container	Preserve in a tight container
Child Safety	Keep out of the sight and reach of children

---

Disposal

Official labeling for comparable products states no special precautions for disposal are required. Unused or expired Acenac N Tablet must be disposed of in compliance with local environmental and pharmaceutical waste regulations.